Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

Innovation, inclusion, and urgency  define Kigali HIV conference ANALYSIS | RONALD MUSOKE | When the 13th International AIDS ...

South Africa has the world’s largest HIV treatment programme, with over 5. 5 million people receiving antiretrovirals (ARVs).

Through US Agency for International Development (USAid) and Pepfar, America has played a vital role in Kenya’s healthcare ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

Will we-the-quails unite to lift the net or wither away the gains made in AIDS response? By SHOBHA SHUKLA, BOBBY RAMAKANT ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

Newsday Zimbabwe HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

However, despite the Senate's decision to protect Pepfar from President Trump's proposed $400 million (Sh51.6 billion) ...